S-777,469
S-777,469 is a drug developed by Shionogi which is a cannabinoid receptor agonist, with 128x selectivity for the CB2 subtype, having a CB2 affinity of 36nM, and a CB1 affinity over 4600nM. In animal studies it showed antipruritic effects, and passed Phase II human trials for the treatment of atopic dermatitis, but development was ultimately not continued further. See also * BMS-F * RQ-00202730 * S-444,823 S-444,823 is a drug developed by Shionogi which is a cannabinoid agonist. It was developed as an antipruritic, and has moderate selectivity for the CB2 subtype, having a CB2 affinity of 18nM, and 32x selectivity over the CB1 receptor. In anima ... References Cannabinoids 2-Pyridones Cyclohexanecarboxylic acids 4-Fluorophenyl compounds {{cannabinoid-stub ...
[...More Info...]       [...Related Items...]     OR:     [Wikipedia]   [Google]   [Baidu]